EHC · Encompass Health Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59B | - | $1.48B | $1.46B | $1.46B | - | $1.35B | $1.30B | $1.32B | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $58.20M | - | $56.10M | $59.40M | $52.30M | - | $54.00M | $50.50M | $50.20M | - |
| Total Operating Expenses | $1.28B | - | $1.23B | $1.20B | $1.19B | - | $1.14B | $1.09B | $1.11B | - |
| D&A | $87.30M | - | $82.40M | $79.90M | $79.20M | - | $78.40M | $72.90M | $70.30M | - |
| Operating Income | $288.70M | - | $219.90M | $236.80M | $238.60M | - | $183.80M | $186.00M | $178.40M | - |
| Interest Expense | $31.80M | - | $30.80M | $30.40M | $35.20M | - | $34.90M | $36.30M | $35.20M | - |
| Income Tax | $56.40M | - | $44.90M | $51.00M | $41.60M | - | $36.00M | $38.30M | $38.30M | - |
| Net Income | $194.50M | - | $126.50M | $142.10M | $151.50M | - | $108.20M | $114.10M | $112.50M | - |
| EPS - Basic | $1.96 | - | $1.26 | $1.41 | $1.50 | - | $1.08 | $1.13 | $1.12 | - |
| EPS - Diluted | $1.93 | - | $1.24 | $1.39 | $1.48 | - | $1.06 | $1.12 | $1.10 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $110.50M | $72.20M | $48.70M | $99.10M | $95.80M | $85.40M | $147.80M | $154.40M | $134.40M | $69.10M |
| Accounts Receivable | $676.00M | $613.40M | $610.80M | $612.50M | $623.40M | $593.00M | $576.40M | $589.70M | $619.30M | $599.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $204.00M | $178.20M | $138.40M | $174.50M | $159.10M | $171.00M | $170.30M | $164.20M | $166.10M | $170.00M |
| Current Assets | $1.03B | $905.90M | $869.80M | $918.10M | $910.90M | $886.90M | $933.90M | $938.10M | $929.80M | $841.80M |
| Total Assets | $7.31B | $7.09B | $6.87B | $6.79B | $6.64B | $6.53B | $6.46B | $6.39B | $6.23B | $6.10B |
| Current Liabilities | $876.80M | $836.40M | $762.00M | $865.10M | $856.00M | $841.00M | $897.40M | $694.50M | $680.30M | $656.40M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.95B | $3.81B | $3.68B | $3.70B | $3.70B | $3.69B | $3.73B | $3.86B | $3.83B | $3.81B |
| Stockholders' Equity | $2.52B | $2.44B | $2.37B | $2.28B | $2.16B | $2.07B | $1.96B | $1.84B | $1.74B | $1.65B |
| Retained Earnings | - | $1.29B | - | - | - | $796.70M | - | - | - | $406.50M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $313.10M | - | - | - | $288.60M | - | - | - | $238.80M | - |
| Investing Cash Flow | ($150.10M) | - | - | - | ($158.50M) | - | - | - | ($129.70M) | - |
| Financing Cash Flow | ($102.50M) | - | - | - | ($130.40M) | - | - | - | ($40.60M) | - |
| CapEx | $162.40M | - | - | - | $163.10M | - | - | - | $139.40M | - |
| Free Cash Flow | $150.70M | - | - | - | $125.50M | - | - | - | $99.40M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 18.2% | - | 14.9% | 16.2% | 16.4% | - | 13.6% | 14.3% | 13.6% | - |
| EBITDA margin | 23.7% | - | 20.5% | 21.7% | 21.8% | - | 19.4% | 19.9% | 18.9% | - |
| Net margin | 12.3% | - | 8.6% | 9.7% | 10.4% | - | 8.0% | 8.8% | 8.5% | - |
| Free cash flow margin | 9.5% | - | - | - | 8.6% | - | - | - | 7.6% | - |
| FCF / Net income | 0.77 | - | - | - | 0.83 | - | - | - | 0.88 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 3.7% | - | 3.8% | 4.1% | 3.6% | - | 4.0% | 3.9% | 3.8% | - |
| Effective tax rate | 22.5% | - | 26.2% | 26.4% | 21.5% | - | 25.0% | 25.1% | 25.4% | - |
| Return on assets | 2.7% | - | 1.8% | 2.1% | 2.3% | - | 1.7% | 1.8% | 1.8% | - |
| Return on equity | 7.7% | - | 5.3% | 6.2% | 7.0% | - | 5.5% | 6.2% | 6.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.17 | 1.08 | 1.14 | 1.06 | 1.06 | 1.05 | 1.04 | 1.35 | 1.37 | 1.28 |
| Quick ratio | 1.17 | 1.08 | 1.14 | 1.06 | 1.06 | 1.05 | 1.04 | 1.35 | 1.37 | 1.28 |
| Cash ratio | 0.13 | 0.09 | 0.06 | 0.11 | 0.11 | 0.10 | 0.16 | 0.22 | 0.20 | 0.11 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 9.1x | - | 7.1x | 7.8x | 6.8x | - | 5.3x | 5.1x | 5.1x | - |
| Equity multiplier | 2.90 | 2.91 | 2.89 | 2.98 | 3.08 | 3.16 | 3.30 | 3.47 | 3.58 | 3.70 |
| Liabilities / Assets | 0.54 | 0.54 | 0.54 | 0.54 | 0.56 | 0.56 | 0.58 | 0.60 | 0.61 | 0.62 |
| Efficiency | ||||||||||
| Asset turnover | 0.22 | - | 0.22 | 0.21 | 0.22 | - | 0.21 | 0.20 | 0.21 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 156d | - | 151d | 153d | 156d | - | 156d | 165d | 172d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 50.1x | - | 102.4x | 88.2x | 68.4x | - | 91.2x | 76.6x | 75.1x | - |
| P / B | 3.9x | - | 5.5x | 5.5x | 4.8x | - | 5.0x | 4.8x | 4.8x | - |
| P / S | 6.1x | - | 8.8x | 8.6x | 7.1x | - | 7.3x | 6.7x | 6.4x | - |
| EV / EBITDA | 25.6x | - | 42.8x | 39.3x | 32.2x | - | 37.1x | 33.2x | 33.4x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 9.0% | - | 9.4% | 12.0% | 10.6% | - | 11.9% | 9.6% | 13.4% | - |
| Revenue CAGR (3y) | 11.0% | - | 10.7% | 3.1% | 3.0% | - | 1.7% | 0.3% | 2.3% | - |
| Revenue CAGR (5y) | 5.2% | - | 4.7% | 6.3% | 4.2% | - | 3.1% | 2.8% | 3.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 21.0% | - | 19.6% | 27.3% | 33.7% | - | 26.8% | 23.0% | 22.0% | - |
| Net income growth (YoY) | 28.4% | - | 16.9% | 24.5% | 34.7% | - | 26.8% | 24.8% | 28.3% | - |
| EPS growth (YoY) | 30.4% | - | 17.0% | 24.1% | 34.5% | - | 26.2% | 24.4% | 26.4% | - |
| EPS CAGR (3y) | 30.4% | - | 40.2% | 41.6% | 19.4% | - | 2.0% | -0.3% | 0.9% | - |
| EPS CAGR (5y) | 12.5% | - | 9.7% | 32.5% | 11.2% | - | 1.6% | 4.0% | 1.3% | - |
| FCF growth (YoY) | 20.1% | - | - | - | 26.3% | - | - | - | -24.3% | - |
| FCF CAGR (5y) | 20.3% | - | - | - | - | - | - | - | 2.6% | - |
| Book value growth (YoY) | 16.8% | 18.0% | 21.1% | 24.0% | 24.0% | 25.5% | 25.6% | 24.7% | 25.9% | 25.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$5.94B totalInpatient Rehabilitation$5.94B · 100.0%
Product / service
$5.94B totalInpatient$5.76B · 97.0%
Other$178.90M · 3.0%
Peer comparison
Same SIC group: Services-Hospitals
Comparing Encompass Health Corp against the 3 most active filers in the same SIC group.
Dividends
$0.74/share trailing 12 months · +12.1% YoY
| Ex-date | Per share |
|---|---|
| Apr 1, 2026 | $0.1900 |
| Jan 2, 2026 | $0.1900 |
| Oct 1, 2025 | $0.1900 |
| Jul 1, 2025 | $0.1700 |
| Apr 1, 2025 | $0.1700 |
| Jan 2, 2025 | $0.1700 |
| Oct 1, 2024 | $0.1700 |
| Jul 1, 2024 | $0.1500 |
| Mar 28, 2024 | $0.1500 |
| Dec 29, 2023 | $0.1500 |
| Sep 29, 2023 | $0.1500 |
| Jun 30, 2023 | $0.1500 |
| Mar 31, 2023 | $0.1500 |
| Dec 30, 2022 | $0.1500 |
| Sep 30, 2022 | $0.1500 |
| Jul 12, 2022 | $0.2800 |
| Mar 31, 2022 | $0.2228 |
| Dec 31, 2021 | $0.2228 |
| Sep 30, 2021 | $0.2228 |
| Jun 30, 2021 | $0.2228 |
| Mar 31, 2021 | $0.2228 |
| Dec 31, 2020 | $0.2228 |
| Sep 30, 2020 | $0.2228 |
| Jun 30, 2020 | $0.2228 |